Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

EORTC Trial results show that Prophylactic Cranial Irradiation in Small Cell Lung Cancer significantly increases survival

16.08.2007
Trial Results published today in the New England Journal of Medicine expected to change medical practice in Europe and US

Small cell lung cancer (SCLC) is an aggressive tumor that constitutes nearly 15% of all newly diagnosed lung cancers. The majority of patients with SCLC present with extensive disease (ED) at diagnosis, meaning that the cancer has spread to other areas of the body.

Without treatment, consisting of chemotherapy, the median survival is two to four months. Despite treatment, in most patients, disease progression will lead to dead within one year. Cancer spreading to the brain is an important cause of death and has a profound negative effect on psychological and physical functioning.

Background
Studies conducted primarily in the 1980 had shown that for patients with limited SCLC and complete response to chemotherapy, prophylactic brain irradiation reduced the risk of brain metastasis and improved survival.

In the EORTC 08993-22993 study, Ben Slotman, MD, PhD, Professor of Radiation Oncology at the VU University medical center in Amsterdam, and his European colleagues from the EORTC Radiation Oncology and Lung Cancer Groups extended the use of prophylactic cranial irradiation (PCI) to patients with extensive SCLC. 286 patients were randomized to either receive prophylactic irradiation or to being observed, following four to six cycles of chemotherapy that induced a response of their SCLC.

Results of the study

One year after being randomized in the trial, only 14.4 % of the patients that received PCI suffered from symptomatic spread of their cancer to the brain, compared with 40.4 % of the patients who did not receive PCI. Moreover, 27.1% of the patients receiving PCI were alive after one year, compared with 13.3% of the patients who were not prophylactically irradiated.

Why this study is important:

“Prophylactic cranial irradiation significantly reduces the risk of symptomatic brain metastases and significantly prolongs survival” according to Prof Slotman. “As this treatment is well tolerated and does not adversely influence quality of life, prophylactic cranial irradiation should now routinely be offered to all SCLC patients with extensive disease whose cancer responds to chemotherapy.”

For Roy S Herbst, MD, PhD, Professor of Medicine in the Department of Thoracic/Head and Neck Medical Oncology, University of Texas/Section Chief of Thoracic Medical oncology at the MD Anderson Cancer center in Houston, Texas, the results of this study represented the most important clinical finding for the treatment of patients with lung cancer presented at ASCO 2007 in June this year. “I expect prophylactic cranial irradiation will be taken up quickly in the US, as well” he commented in an interview during ASCO 2007.

“Furthermore, this trial was impressive because it showed that a standard modality, such as radiation therapy, still has the potential to improve survival. In this era of targeted therapies, we cannot forget that standard modalities can still improve disease outcomes.” he adds.

Moreover, the trial results give weight to the further research hypothesis that thoracic radiotherapy - using the nowadays advanced radiotherapy techniques - might be beneficial to this pretreated patient group as well - a hypothesis Prof Ben Slotman and colleagues are preparing to test in clinical randomized trial to run in The Netherlands, the UK and possibly more European countries.

“The challenge in the future remains how to integrate the current modalities with the newer targeted modalities. This EORTC trial shows once again that in clinical cancer research, pursuing a multidisciplinary research agenda can be crucial for improving patient survival.” explains Françoise Meunier, MD, PhD, Director General of the EORTC.

Reference:
Slotman, B.; Faivre-Finn, C. (2007). Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer. NEJM 357: 664-672.
For further information about the study, please contact:
Ben J Slotman, MD, PhD
Department of Radiation Oncology
VU University Medical Center in Amsterdam – The Netherlands
Tel.: +31 20 4440414 Email: bj.slotman@vumc.nl
For further information about the EORTC, please contact:
Françoise Meunier, MD, PhD
Director General, EORTC
Avenue E. Mounier 83/11
B – 1200 Brussels / Belgium
Email: Francoise.Meunier@eortc.be
About the EORTC:
Created in 1962, the European Organisation for Research and Treatment of Cancer (EORTC) is a not-for-profit international cancer research organisation under the Belgian law.
The EORTC has the mission to develop, conduct, coordinate and stimulate translational and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patients’ quality of life. The ultimate goal of the EORTC is to improve the standard of cancer treatment in Europe, through the evaluation of new drugs and other innovative approaches, and to test more effective therapeutic strategies, using drugs which are already commercially available, or surgery or radiotherapy.
The EORTC has the aim to facilitate the passage of experimental discoveries into state-of-the-art treatment by keeping to a minimum the time lapse between the discovery of new anti-cancer agents and the implementation of their therapeutic benefit for patients with cancer.

The EORTC promotes multidisciplinary cancer research in Europe and is linked to other leading biomedical research organisations around the world. EORTC research takes place in over 300 hospitals, universities and cancer centers in 32 countries, and the unique network of investigators of the EORTC comprises more than 2000 clinicians collaborating on a voluntary basis in 19 multidisciplinary groups.

For any further information related to the research activities of the EORTC, please consult the EORTC website: www.eortc.be

Nicole Heine | alfa
Further information:
http://www.eortc.be

More articles from Health and Medicine:

nachricht Satellites, airport visibility readings shed light on troops' exposure to air pollution
09.12.2016 | Veterans Affairs Research Communications

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Electron highway inside crystal

Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.

Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Researchers identify potentially druggable mutant p53 proteins that promote cancer growth

09.12.2016 | Life Sciences

Scientists produce a new roadmap for guiding development & conservation in the Amazon

09.12.2016 | Ecology, The Environment and Conservation

Satellites, airport visibility readings shed light on troops' exposure to air pollution

09.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>